“Latest Stem Cells News”

Image via Wikipedia

Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes.

The endometrium, or uterine lining, is a source of adult stem cells. Normally, these cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.

The study’s findings suggest the possibility that endometrial stem cells could be used to develop insulin-producing islet cells. These islet cells could then be used to advance the study of islet cells transplantation as a treatment for people with diabetes. If the transplantation of islet cells derived from endometrial cells is perfected, the study authors write that women with diabetes could provide their own endometrial tissue for such a transplant, sidestepping the chance of rejection posed by tissue from another person. Endometrial stem cells are readily available and can be collected easily during a simple outpatient procedure. Endometrial tissue could also be collected after hysterectomy, the surgical removal of the uterus.

“The study findings are encouraging,” said Louis V. DePaolo, Ph.D., chief of the Reproductive Sciences Branch at the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which funded the study. “Research to transplant insulin-producing cells into patients with diabetes could proceed at a much faster pace with a relatively accessible source of donor tissue.”

The study authors note that such a treatment would be more useful for people with Type 1 diabetes, in which no insulin is produced. The treatment would be less useful for Type 2 diabetes, in which insulin is usually produced, but in which cells have difficulty using the insulin that is available.

The findings appear in Molecular Therapy. The study was conducted by Xavier Santamaria, Efi E. Massasa, Yuzhe Feng, Erin Wolff and Hugh Taylor, M.D., all of Yale University, New Haven, Conn.

Incoming search terms:

Alan Lewis of the Juvenile Diabetes Research Foundation distinguishes type 1 and type 2 diabetes, and continues to explain how stem cells are being used today to develop new treatments for type 1 diabetes (a.k.a. juvenile diabetes). Human embryonic stem cells (hESC) are being differentiated to the beta (insulin producing) cells that type 1 diabetics lack, and are being transplanted , in animal models. Since type 1 diabetes is an auto-immune disease, the transplanted cells must be protect from destruction by the immune system. Currently, researchers are working towards that goal with encapsulating technologies and a “gentle” immuno-modulation. In order to treat a diabetic patient, access to an unlimited number of cells is necessary. Alan compares embryonic stem cells, adult stem cells, and iPS as source of cells. And finally, in a future outlook, Alan comments on the FDA’s concern for safety, the risk of creating a tumor, artificial pancreas (as an alternative approach), and cell therapy‘s potential to CURE diseases

from http://biobusiness.tv/videos/223

Incoming search terms:

Dr. Roberto Fernandez Vina is scheduled to present a stem cell research study in which he helped improve Diabetes Type 2 patients with their own Adult Stem Cells and followed up on them for 3 years! The stem cell treatment and therapy was a great success. The results are below.

Stem Cell Pioneer and Doctor to Present Adult Stem Cell Study At ISSCR Meeting

Dr. Fernandez Vina will present the following abstract at the International Society for Stem Cell Research (ISSCR) annual meeting in Barcelona in July 2009.  This is another milestone in Adult Stem Cell research as Dr. Fernandez-Vina has probably been the world’s foremost stem cell doctor in helping patients with their own stem cells.

FIRST REPORT FROM ARGENTINA OF FIRST THREE YEARS FOLLOW UP OF AUTOLOGOUS STEM CELLS IMPLANT IN DIABETES TYPE 2

Objectives: To evaluate the long time performance of Stem cells implant in pancreas in Diabetes Type 2 patients The adults stem cells CD34(+)CD38(-) have demonstrated the capacity to differentiate into functional cells in the endocrine pancreas.

Method: After three years on cell therapy for diabetes,patients the conclusions are optimistic. In this study were observed the evolution of 58 patients Diabetic type 2, 37 male, 21 female, 29- 71 years old. 29 patients were under insulin therapy, and 20 patients using Sulphonylureas + Biguanides. For the transplantation, we harvested bone marrow from the iliac crest by aspiration. The sample was processed using a density gradient separation method, obtaining 120ml (±95) of CD34(+)CD38(-) solution. For the implant was procedure a catheterization through Splenic Artery. No complications or further events were observed during or after the procedure. The patients were subjected to clinical and blood samples control during the 36 months following the implant.

Conclusions: the implant of mononuclear CD34+CD38- ( stem cells) from autologous bone marrow improve pancreatic function in patients with type 2 diabetes, in a safe form and is maintained after 3 years at least

Stem Cell Treatment Now Available, But Not In the United States

Dr. Fernandez Vina from Argentina now is treating patients with their own stem cells in Argentina as well as El Salvador (a short flight from Houston) for conditions such as Spinal Cord Injury, Heart Disease, Lung Diseases (COPD and Emphysema) Diabetes Type 1 and Diabetes Type 2 as well as many other conditions.

If you are further interested in this Adult Stem Cell treatment, please go to our Repair Stem Cell Institute website and fill out this stem cell treatment request form and we will assist you in receiving more stem cell therapy information regarding Dr. Fernandez Vina

original post by Don Margolis

Incoming search terms: